Show simple item record

dc.contributor.authorWilliams, Jessica
dc.contributor.authorWatkeys, Laura
dc.contributor.authorNash, J.
dc.contributor.authorWhelan, C.
dc.contributor.authorDavies, A.J.
dc.contributor.authorEvans, J.
dc.contributor.authorMorris, Keith
dc.contributor.authorJames, Philip
dc.date.accessioned2021-04-16T08:53:22Z
dc.date.available2021-04-16T08:53:22Z
dc.date.issued2021-02-26
dc.identifier.citationWilliams, J.O., Watkeys, L., Nash, J., Whelan, C., Davies, A.J., Evans, J., Morris, K.M. and James, P.E. (2021) 'A Two-Phase, Single Cohort Study of COVID-19 Antibody Sera-Surveillance', Annals of Epidemiology and Public Health, 4(1): 1055en_US
dc.identifier.issn2639-4391
dc.identifier.urihttps://meddocsonline.org/annals-of-epidemiology-and-public-health/a-two-phase-single-cohort-study-of-COVID-19-antibody-sera-surveillance.pdf
dc.identifier.urihttp://hdl.handle.net/10369/11353
dc.descriptionArticle published in Annals of Epidemiology and Public Health available open access at : http://meddocsonline.org/en_US
dc.description.abstractObjective: The infectious corona virus, COVID-19 has high case mortality in those whom suffer with severe symptoms requiring hospitalisation. A major problem associated with COVID-19 is the spread of infection by a-symptomatic carriers, or those with mild symptoms. We aim to determine the antibody prevalence in a professional Welsh cohort and begin to explore the longevity of COVID-19 antibodies. Methods: 739 Cardiff Metropolitan University staff members took part in an observational study to determine the prevalence of COVID-19 antibodies in a two-phase, single cohort study. All participants were tested for IgM and IgG antibodies against COVID-19 using a lateral flow detection assay. Venous blood samples from positive participants and a randomly selected negative population were collected to confirm antibody titre, using two gold standard immunoassays, carried out independently by the Specialist Virology Centre, UHW. Results: 3.65% of the population tested positive for antibodies against COVID-19, with a higher prevalence seen in male participants (5% vs. 2.73% of females). In addition to gender, both pre-existing asthma and age were key determinants in antibody positivity. 78.26% retained antibodies at the 3 months follow up test. 36.36% of females lost antibody positivity between the 3 - and 6 - month time points compared with 8.3% of males. Lateral flow antibody testing was shown to have 96% sensitivity and 95% specificity compared with standard tests. Conclusion: We conclude that prevalence of COVID-19 antibodies is evident in the asymptomatic population, and in 78.26% of those initially antibody positive prevails at approximately 6 months from perceived time of exposure. Males are 4 times more likely to retain antibodies for longer than females.en_US
dc.language.isoenen_US
dc.publisherMedDocsen_US
dc.relation.ispartofseriesAnnals of Epidemiology and Public Health;
dc.subjectepidemiologyen_US
dc.subjectCOVID-19 antibodiesen_US
dc.titleA Two-Phase, Single Cohort Study of COVID-19 Antibody Sera-Surveillanceen_US
dc.typeArticleen_US
dcterms.dateAccepted2021-02-23
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionVoRen_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en_US
rioxxterms.licenseref.startdate2021-04-16
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record